Duque Eduardo J, Giachelli Cecilia, Moysés Rosa M A
Division of Nephrology and Hypertension, Center for Translational Metabolism and Health, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Department of Bioengineering, University of Washington, Seattle, Washington, USA.
Curr Opin Nephrol Hypertens. 2025 Jul 1;34(4):291-296. doi: 10.1097/MNH.0000000000001074. Epub 2025 Apr 1.
Chronic kidney disease-mineral bone disorder (CKD-MBD) is associated with several adverse outcomes, including bone fragility and sarcopenia. Identification of new agents mitigating systemic damage related to uremia is critical and needed to unveil pathways implicated in CKD-MBD.
Osteopontin (OPN) is involved in different physiological and pathological processes and works as a bridge connecting several systems. It may serve as a biomarker for many diseases, including human cancers, neurodegenerative disorders and autoimmune diseases. OPN has been implicated in disturbances of bone mineralization and remodeling, and has an interplay with parathyroid hormone and FGF23 in experimental models. In patients with CKD and severe hyperparathyroidism, OPN expression in muscle tissue has been linked to worse functionality and local inflammation, which is partially reverted after parathyroidectomy.
Future studies could confirm the role of OPN as a biomarker in nephrology. Greater understanding of its role in CKD-MBD will help us define a better therapeutic strategy in patients with CKD.
慢性肾脏病-矿物质和骨异常（CKD-MBD）与多种不良后果相关，包括骨脆性增加和肌肉减少症。识别减轻与尿毒症相关的全身损害的新药物至关重要，这对于揭示CKD-MBD中涉及的途径是必要的。
骨桥蛋白（OPN）参与不同的生理和病理过程，并作为连接多个系统的桥梁发挥作用。它可能作为多种疾病的生物标志物，包括人类癌症、神经退行性疾病和自身免疫性疾病。在实验模型中，OPN与骨矿化和重塑的紊乱有关，并与甲状旁腺激素和FGF23相互作用。在患有CKD和严重甲状旁腺功能亢进的患者中，肌肉组织中OPN的表达与较差的功能和局部炎症有关，甲状旁腺切除术后这种情况会部分得到改善。
未来的研究可以证实OPN作为肾脏病学生物标志物的作用。对其在CKD-MBD中作用的更深入了解将有助于我们为CKD患者制定更好的治疗策略。
